Novo Nordisk (NVO.US) scores another victory in the GLP-1 field: Wegovy approved by FDA for treating liver disease, nearly 15 million American patients eligible.

Zhtng Cijng APP huzh, nu h nu d (NVO.US) chngxio jinfi yo Wegovy y hu d Migu shpn yo f huzhngunlj (FDA) de pdng, k yng y zhlio y zhng ynzhng de dnzng jbng. Gi gngs cj jbi le jngzhng dushu l li (LLY.US), lxin jing gi yow tuxing le Migu shchng, ynwi zh zhng bngzhng zi mi zhng bin d yu li yu chngjin. Gi yow shyng y bnh zhngd zh zhngd gnyngfibo (2 qhu 3 q) de fi dn qngxng xng di mi gngnng zhng'i xinggun zhfngxng gnyng hpnp (MASH) chng rn hunzh.